期刊
LANCET NEUROLOGY
卷 9, 期 1, 页码 119-128出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(09)70299-6
关键词
-
资金
- National Institute on Aging (Us National Institutes of Health) [AG11378, AG16574, MCSA AG06786]
- Alzheimer's Disease Center [AG10124]
- NATIONAL INSTITUTE ON AGING [R01AG011378, U01AG006786, P50AG016574, U19AG010483, P30AG010124] Funding Source: NIH RePORTER
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (A beta) peptide, ultimately leading to formation of A beta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF A beta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which A beta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据